PTI, PANJIM: Drug firm Indoco Remedies today said the US
health regulator has inspected its Goa plant and has issued six observations on
account of violation of good manufacturing norms.
“The United States Food and Drug Administration (USFDA)
inspected the company’s Goa Plant II from August 31, 2016 to September 4,
2016,” Indoco Remedies said in a BSE filing.
If you enjoyed reading this article, you can help support our journalism by adding OHeraldo as a preferred source.
The injectable abbreviated new drug application (ANDA)
filings triggered this inspection, it added.
“At the end of the inspection, six 483s (forms) were
issued. All the observations(483s) are correctable and the company expects to
complete the corrective and preventive actions within a period of 30
days,” Indoco Remediessaid.
None of the 483s are related to data integrity issue, it
added.
As per the FDA, “an FDA Form 483 is issued to firm
management at the conclusion of an inspection when an investigator(s) has
observed any conditions that in their judgement may constitute violations of
the Food Drug and Cosmetic Act and related Acts.”
Shares of Indoco Remedies closed 2.72 per cent higher at Rs
330.05 per scrip on BSE today.
